[Drug interactions of lipid-lowering drugs and precaution of clinical use].
Saito
N
N
Department of Endocrinology and Metabolism, St. Marianna University School of Medicine.
Ogawa
Y
Y
D000837:Anion Exchange Resins / Q000008:administration & dosage / Q000494:pharmacology; D001629:Bezafibrate / Q000008:administration & dosage / Q000494:pharmacology; D016572:Cyclosporine / Q000008:administration & dosage / Q000494:pharmacology; D004077:Digoxin / Q000008:administration & dosage / Q000494:pharmacology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D014859:Warfarin / Q000008:administration & dosage / Q000494:pharmacology
D000837:Anion Exchange Resins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014859:Warfarin; D004077:Digoxin; D016572:Cyclosporine; D001629:Bezafibrate